Introduction
Vascular endothelial growth factor (VEGF) is a potent angiogenic factor associated with tumor progression and metastasis in numerous solid and hematopoietic malignancies (reviewed in Folkman, 2001; Stoeltzing et al., 2003) . The VEGF family of ligands includes VEGF-A, -B, -C, -D, -E, and placenta growth factor (PlGF). These ligands bind to three tyrosine kinase receptors: VEGFR-1 (Flt-1), VEGFR-2 (KDR, or the murine homolog Flk-1), and VEGFR-3 (Flt-4), all of which have been well characterized on endothelial cells. All three receptors have extracellular ligand-binding domains that induce intracellular signaling upon binding and receptor dimerization. Initial reports suggested that these receptors were expressed only on endothelial cells (Brown et al., 1993; Detmar et al., 1994) . However, more recent studies have noted these tyrosine kinase receptors on hematopoietic stem cells, monocytes, and osteoblasts (Bellamy et al., 1999; Mayr-Wohlfart et al., 2002; Lalla et al., 2003) . VEGF receptors have also been noted on tumor cells, including leukemic cells, Kaposi's sarcoma, and breast carcinoma (Arora et al., 1999; Dias et al., 2000; Hasan and Jayson, 2001; Price et al., 2001; Ryden et al., 2003) . The novel VEGF co-receptor, neuropilin, has also been shown to be present on tumor cells and may mediate cell survival signals in breast carcinoma (Bachelder et al., 2003) . However, the function of the VEGF tyrosine kinase receptors on tumor cells remains to be elucidated.
Of the three VEGFR tyrosine kinases, VEGFR-2 is the best characterized to date. In endothelial cells, VEGF activates standard signaling pathways such as the phosphoinositide 3-kinase/AKT and mitogen-activated protein kinase (MAPK) pathways (Gerber et al., 1998; Takahashi et al., 1999) . Intracellular signaling leads to endothelial cell activation, including upregulation of degradative enzymes, induction of vascular permeability, and enhanced survival mechanisms (Shaheen et al., 2001; Chen et al., 2002; Patel et al., 2003) . VEGFR-1 has been associated with cell migration (Barleon et al., 1996) , whereas VEGFR-3 is typically associated with lymphangiogenesis in adults (Irrthum et al., 2000) .
Here we investigated the possibility that VEGF receptors are present on colorectal carcinoma (CRC) cells. Protein analyses of seven CRC cell lines showed that VEGFR-1 was expressed in all seven cell lines. We found that activation of VEGFR-1 with specific ligands led to induction of intracellular signaling, enhancement of cell migration and invasion, and increased colony formation in soft agar. Interestingly, activation of VEGFR-1 on tumor cells did not lead to an increase in proliferation. In light of recent findings that anti-VEGF therapy enhances the effect of standard chemotherapy in patients with metastatic CRC (Hurwitz et al., 2004) , these findings have potential implications for designing therapy to target the VEGF/receptor pathway.
Results

Expression of VEGFR-1 mRNA and protein by CRC cell lines
RT-PCR demonstrated VEGFR-1 expression in 9/9 cell lines studied (data not shown). Western blotting confirmed the expression of VEGFR-1 protein in seven of seven CRC cell lines, with human umbilical vein endothelial cells (HUVECs) used as positive controls ( Figure 1a) . ELISA demonstrated that all seven CRC cell lines expressed VEGFR-1 at a range of 2-400 pg/mg protein. FACS analysis confirmed the expression of VEGFR-1 in CRC cell lines (data not shown). CRC cells did not express VEGFR-2 mRNA or protein by RT-PCR and ELISA, respectively. Similarly, the cells did not express VEGFR-3 by RT-PCR or Western blot (data not shown).
VEGR-1 expression in human surgical specimens of primary cancers and liver metastases
Immunohistochemical staining of uninvolved colon mucosa, primary colon cancer, and liver metastasis was carried out to determine expression of VEGFR-1 in resected surgical specimens. VEGFR-1 was not detectable in nonmalignant mucosa. VEGFR-1 expression was faint in eight of 10 primary colon cancer specimens. However, VEGFR-1 expression was detected in six of nine evaluable liver metastases (Figure 1b ).
Effects of VEGF-A and -B on signal transduction pathways in CRC cell lines
To identify the signaling pathways activated by VEGFR-1, we treated HT-29 cells with VEGF-A or -B for various periods and analysed signaling intermediates by Western blotting. VEGF-A and -B induced Erk-1/2 activation with peak phosphorylation at 15 min and returned to baseline levels by 30 min. VEGF-A and -B activated JNK by 15 min (Figure 2a) . In contrast, phosphorylation of Akt remained unchanged throughout the time period studied (data not shown).
Similar inductions of Erk-1/2 and SAPK/JNK phosphorylation were observed in a second CRC cell line, SW480 (Figure 2b ). Pretreatment of cells with VEGFR-1 antibody, 18F1, totally blocked induction of VEGF-A We examined the effect of VEGF-A or -B on nuclear factor-kB (NF-kB) p65 translocation into the nucleus of CRC cells. The cells were treated with VEGF-A or-B for 30 min and nuclear protein was extracted and tested for NF-kB p65 by Western blotting. In both cell lines (HT29, SW480), VEGF-A and -B led to an increase in NF-kB p65 translocation into the nucleus (Figure 2c ).
VEGF-A or -B enhances CRC cell migration
To test the ability of VEGFR-1 to mediate enhanced migration in response to VEGF-A or -B, we treated HT-29 cells with 10 mg/ml of the anti-VEGFR-1 antibody, 18F1, or 10 mg/ml of the anti-VEGFR-2 antibody, 1121B for 1 h, seeded them in modified Boyden chambers in medium (with 10% FBS) containing or not containing VEGF-A or -B, and assessed migration 48 h later. Cell lines showed an increase in migration in response to VEGF-A or B, and 18F1 blocked this migration (Po0.0001vs control). In contrast, blockade of VEGFR-2 with 1121B did not block the effect of ligand on migration (data not shown) ( Figure 3 ). Similar results were observed in SW480 cells (Po0.05 vs control, data not shown).
VEGF-A or -B enhances CRC cell invasion
As HT-29 cells are not particularly invasive under basal or stimulated conditions, we used SW480 cells to test the ability of VEGFR-1 to mediate invasion in response to VEGF-A or -B. Cells were treated as described in Materials and methods (modified Boyden chamber assays with Matrigel coating of the membrane) and invasion was determined at 48 h. Again, SW480 cells treated with VEGF-A or -B invaded the membranes at significantly higher rates than did cells in control medium, and an antibody to VEGFR-1 blocked this invasion (Po0.05 vs control) (Figure 4 ), whereas the VEGFR-2 antibody did not.
VEGF-A or VEGF-B enhances CRC cell growth in soft agar
To investigate the anchorage-independent growth of CRC cells, we plated HT-29 cells in soft agar with or without VEGF-A, -B, or VEGFR-1 antibody, and counted the colonies that had formed at 14 days. Cells treated with VEGF-A or -B formed more and larger colonies than control (10% MEM-FBS only) cells. Treatment with the anti-VEGFR-1 antibody suppressed the induction of colony formation by VEGF-A or -B (Po0.03 vs control) ( Figure 5 ). Nonspecific IgG control antibody had no effect (data not shown). 
VEGF-A or -B does not affect CRC cell proliferation
For these experiments, CRC cells were stimulated with VEGF-A and -B and counted 24, 48, 72, and 96 h thereafter. Neither VEGF-A nor -B caused an increase in cell proliferation compared with control (data not shown).
Discussion
In this investigation of the expression and function of VEGFR-1 on CRC cells, we found that activation of VEGFR-1 on CRC cells with VEGF-A or -B induces downstream signaling, including activation of the Erk-1/ 2 and JNK MAPK pathways. We further showed that addition of these cytokines led to functional changes, including increased cell migration, invasion, and colony formation. However, VEGFR-1 activation did not increase cell proliferation. Blockade of VEGFR-1 with a neutralizing monoclonal antibody inhibited these processes, demonstrating that these effects are being mediated via activation of VEGFR-1 and not some other receptor. VEGFR-1 was originally thought to be a receptor that was specifically expressed on vascular endothelial cells (Brown et al., 1993; Detmar et al., 1994) that had a relatively minor role in VEGF-mediated signal transduction, as none of the traditional effects of VEGF (e.g., increased cell proliferation) were seen in response to its stimulation (Waltenberger et al., 1994) . However, the importance of VEGFR-1 in angiogenesis was established through transgenic mouse studies in which homozygous knockout of VEGFR-1 produced early embryonic death characterized by disorganized blood vessels and endothelial cell overgrowth (Fong et al., 1995) . More recent studies have confirmed the importance of VEGFR-1 in a variety of normal cells, where it has been shown to regulate monocyte migration (Barleon et al., 1996; Clauss et al., 1996) , recruitment of endothelial cell progenitors (Lyden et al., 2001) , increases in the adhesive properties of natural killer cells (Chen et al., 2002) , and induction of growth factors from liver sinusoidal endothelial cells (LeCouter et al., 2003) . Other studies have shown VEGFR-1 to be expressed on tumor cells and have implicated it in tumor growth and progression (von Marschall et al., 2000; Masood et al., 2001; La Rosa et al., 2003) . In studies of pancreatic adenocarcinoma cells, activation of the receptor with its ligand was shown to induce phosphorylation of the tyrosine kinase domain, suggesting that the receptor is functional in these cells. VEGFR-1 expression has also been demonstrated on human prostate and breast carcinoma cells (Hahn et al., 2000; Zhukova et al., 2003) . However, except for increasing cell proliferation (which was not observed in our studies), the functional significance of the above observations remains to be determined.
We found effects on signaling, survival, migration, and invasion following treatment with VEGF-A (a ligand that binds VEGFR-1 and -2), and VEGF-B (specific to VEGFR-1) (Olofsson et al., 1998) . VEGF-A has been shown to regulate many steps of the angiogenic process, including degradation of the basement membrane and extracellular matrix, endothelial cell migration, proliferation, permeability, and tube formation (reviewed in Ferrara and Davis-Smyth, 1997); most of these effects are thought to be mediated through VEGFR-2. VEGF-B is a secreted growth factor that has B45% sequence homology with VEGF-A and is a primary regulator of vasculogenesis/angiogenesis in cardiovascular development and in corpus luteum formation (reviewed in Ferrara, 1999) . VEGF-B has been shown to selectively bind and activate VEGFR-1 (Olofsson et al., 1998) . As none of the CRC cell lines studied here expressed VEGFR-2, we contend that the effects of VEGF-A and -B are mediated through activation of VEGFR-1, a concept confirmed by the addition of a specific VEGFR-1-blocking antibody. The moderate difference in effects between VEGF-A and VEGF-B on signaling and migration may be related to dose or perhaps to the binding of these ligands to different regions of the extracellular domain of VEGFR-1, as is the case with PlGF and VEGF-A. RT-PCR and Western blot analysis indicated that VEGF-B was expressed by seven of seven CRC cell lines utilized in this study (not shown), suggesting that VEGF ligands may be involved in an autocrine loop activating VEGFR-1. PlGF, which also acts as a ligand for VEGFR-1 (Aiello et al., 1994) , was also expressed by two of seven of the CRC cell lines tested (RT-PCR data not shown) and hence may be implicated as well. Although our studies demonstrate a role for VEGFR-1 in steps involved in tumor progression and metastasis, it is unknown what role neuropilin-1 (NRP-1) plays in modifying these effects. NRP-1 is a co-receptor for specific isoforms of VEGF and increases the binding affinity to VEGFR-1 and -2. In other studies, we have shown that NRP-1 is expressed in CRC cells, including cells utilized in these studies (Parikh et al., 2004) . However, the fact that blocking antibodies to VEGFR-1 inhibited phenotypic changes induced by the ligands suggests that VEGFR-1 activity is essential for VEGFinduced phenotypic changes.
In summary, our results demonstrate that VEGFR-1 is expressed on CRC cells and that its activation leads to phenotypic changes associated with steps in the process of tumor progression and metastasis. Although the addition of anti-VEGF therapy to chemotherapy has been demonstrated to be of value in patients with CRC (Hurwitz et al., 2004) , the presence of VEGFR-1 on CRC tumor cells implies that, in addition to the antiangiogenic effects of anti-VEGF/VEGFR therapies, these treatments may also have a direct effect on tumor cells. It is also possible that VEGFR-1 expression on CRC cells may serve as a 'predictive factor' for anti-VEGF/receptor-targeted antineoplastic regimens. A better understanding of the expression and function of the VEGF family in CRC will facilitate the development of targeted therapies and their associated biological markers for predicting response.
Materials and methods
Reagents
Recombinant human VEGF-A (165) and -B were purchased from R&D Systems, Inc. (Minneapolis, MN, USA) and used at 10 ng/ml (VEGF-A) or 50 ng/ml (VEGF-B) unless otherwise specified. Antibodies for Western blot analysis were as follows: polyclonal rabbit anti-phospho-p44/42 MAPK, polyclonal rabbit anti-phospho-Akt, polyclonal rabbit anti-phospho-JNK and NFkB p65 subunit (Cell Signaling Technology, Beverly, MA, USA), and polyclonal goat anti-Flt-1 (VEGFR-1) (Oncogene Research Products, Cambridge, MA, USA). Polyclonal rabbit anti-Flt-4 (VEGFR-3) (Santa Cruz Biotechnology, Inc., CA, USA). VEGFR-1 antibody (18F1) and VEGFR-2 antibody (1121B) for blocking experiments were provided by Daniel J Hicklin, PhD (ImClone Systems).
Cell lines and culture conditions
All human CRC cell lines, except where noted below, were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). KM12L4 and KM12SMLM2 cell lines were obtained from Dr IJ Fidler (The University of Texas MD Anderson Cancer Center). GEO and RKO cell lines were obtained from Dr Douglas Boyd (The University of Texas MD Anderson Cancer Center). Cell lines were cultured in minimal essential medium (MEM) supplemented with 10% fetal bovine serum, penicillin-streptomycin, vitamins, sodium pyruvate, Lglutamine, and nonessential amino acids (Life Technologies, Inc., Grand Island, NY, USA) at 371C in 5% CO 2 and 95% air. Cells were confirmed to be free of Mycoplasma by using Mycoplsama Detection Kit (ATCC, Manassas, VA, USA). Results from all studies were confirmed in at least three independent experiments.
RT-PCR
This assay was performed as described previously (Liu et al., 2002) . Briefly, PCR amplification of VEGFR-1, -2, and -3 was performed under the following conditions: 951C for 5 min, 35 cycles of 30 s denaturing at 951C, 1 min of annealing at 571C, and 1 min of extension at 721C. Products were analysed by electrophoresis of 20 ml of each PCR reaction mixture in a 2% agarose gel, and bands were visualized by ethidium bromide staining. The following primers were used. VEGFR-1: sense primer: 5 0 -TGGGACAGTAGAAAGGGCTT-3 0 and antisense primer: 5 0 -GGTCCACTCCTTACACGACAA-3 0 ; VEG FR-2: sense primer: 5 0 -CATCACATCCACTGGTATTGG-3 0 and antisense primer: 5 0 -GCCAAGCTTGTACCATGTGAG-3 0 ; VEGFR-3: sense primer: 5 0 -CCCACGCAGACATCAA GACG-3 0 and antisense primer: 5 0 -TGCAGAACTCCACGA TCACC-3 0 .
Western blot hybridization
Cells were lysed in protein lysis buffer (20 mM sodium phosphate (pH 7.4), 150 mM sodium chloride, 1% Triton X-100, 5 mM EDTA, 5 mM phenylmethylsulfonyl fluoride, 1% aprotinin, 1 mg/ml leupeptin, and 500 mM Na 3 VO 4 ). Proteins were subjected to electrophoresis on polyacrylamide gels and transferred to nylon membranes (Millipore Corp., Billerica, MA, USA) as described previously . After blocking with 5% milk in 0.1% Tween 20 in TBS, the membranes were probed with primary antibodies (VEGFR-1 antibody 1 : 200 diluted with blocking buffer), washed, and treated with secondary antibody labeled with horseradish peroxidase. Protein bands were visualized with a commercially available chemoluminescence kit (Amersham Biosciences, Piscataway, NJ, USA). HUVECs (American Type Culture Collection, Manassas, VA, USA) were used as a positive control.
Expression of VEGFR-1 on CRC cells determined by FACS
CRC cells were grown to 80% confluence, cells were then trypsinized and counted. In all, 1 million cells were placed into a 5 ml round-bottom tube and washed with cold PBS twice. Cells were then incubated with VEGFR-1 antibody (10 mg) (Santa Cruz, CA, USA) in 100 ml cold PBS for 30 min at 41C. Cells were then washed with cold PBS twice, then incubated with the secondary antibody-FITC anti-rabbit (Jackson ImmunoResearch Laboratories, INC, West Grove, PA, USA) for 30 min at 41C and protect lights. Cells were then washed with cold PBS twice, then re-suspended in 0.5 ml of PBS. Cells immediately underwent FACS analysis (CellQuest Histogram of BD FACSCalibur, BD Biosciences Immunocytometry Systems, San Jose, CA, USA).
Detection of VEGFR-1 in primary and metastatic human CRC specimens
Human colon cancer specimens and liver metastasis were procured under an Institutional Review Board approved protocol. Cryosections (6 mm; frozen in OCT solution) of primary and metastatic colon carcinoma were fixed at room 
Extraction of nuclear protein
HT-29 and SW480 cells (80% confluent) were incubated in 0% MEM-FBS medium overnight and then treated with or without VEGF-A (10 ng/ml) or -B (50 ng/ml) for 30 min. Nuclear protein extraction was performed according to the manufacturer's protocol (Active Motif, Carlsbad, CA, USA) and Western blotting was performed for the NF-kB p65 subunit.
Quantification of VEGFR-1 and -2 protein in CRC cells
Cells were grown to 80-90% confluence, after which they were harvested in protein lysis buffer (from the VEGFR-1 or -2 ELISA kit). The supernatant was collected and centrifuged at 2800 r.p.m. for 5 min and stored at À801C until use. VEGFR-1 or -2 ELISA was performed according to the manufacturer's protocol (R&D Systems Inc., Minneapolis, MN, USA).
Detection of VEGFR-1 in primary and metastatic human CRC specimens
Human colon cancer specimens and liver metastasis were procured under an Institutional Review Board approved protocol. Cryosections (6 mm; frozen in OCT solution) of primary and metastatic colon carcinoma were fixed at room temperature in acetone for 5 min prior to staining with the EnVision þ Mouse Kit (DAKO, Carpinteria, CA, USA) as per kit instructions using anti-VEGFR-1 mAb FB5 (ImClone Systems) and Mouse IgG negative control (Jackson ImmunoResearch, West Grove, PA, USA) at 1 mg/ml. Digital images of positive immunostaining and controls were captured using an Axioskop microscope, Axiocam digital camera, and Axiovision 4.0 software (Zeiss, Thornwood, NY, USA).
Migration and invasion assay
Cell migration and invasion in response to the VEGF ligands were assessed using modified Boyden chambers according to the manufacturer's protocol. Briefly, HT-29 (250 000 cells) or SW480 cells (150 000 cells) in 1% MEM-FBS were incubated with or without the anti-VEGFR-1 antibody 18F1 (10 mg/ml) or anti-VEGFR-2 antibody 1121B (10 mg/ml) or solvent on 8.0-mm pore size membrane inserts (Becton Dickinson Labware, Bedford, MA, USA) in 24-well plates. Chemoattractants (10% MEM-FBS with or without VEGF-A (10 ng/ml) or VEGF-B (50 ng/ml)) were placed in the bottom wells. After 48 h, cells that did not migrate were removed from the top side of the inserts with a cotton swab. Cells that had migrated to the underside of the inserts were stained with Diff-Quik (Harleco, Gibbstown, NJ, USA) and counted in 10 random fields at Â 100 magnification. Results are expressed as means7standard error of the means (s.e.m.).
Colony formation in soft agar
A soft agar assay was used to determine whether activation of VEGFR-1 by the VEGF ligands increased tumor cell survival and anchorage-independent growth. Tumor cells were incubated with or without 18F1 (10 mg/ml) for 1 h and then treated or not treated with VEGF-A (10 ng/ml) or VEGF-B (50 ng/ml) for 4 h. Six-well plates were plated with semisolid medium containing MEM, 1% Bacto-agar, 10% FBS, and penicillinstreptomycin with or without VEGF-A (10 ng/ml) or VEGF-B (50 ng/ml) or VEGFR-1 antibody (10 mg/ml). Cells (250) were then plated in a semisolid medium consisting of MEM with 0.5% Bacto-agar, 10% FBS, and penicillin-streptomycin with or without VEGF-A (10 ng/ml) or VEGF-B (50 ng/ml) or VEGFR-1 antibody (10 mg/ml). Additional medium (10% MEM-FBS with or without VEGF-A (10 ng/ml) or VEGF-B (50 ng/ml) or 18F1 (10 mg/ml)) was added to the wells after 2 days to prevent the agar from drying. After incubation for 14 days at 371C, colonies larger than 50 mm in diameter were counted under a dissecting microscope at Â 40 magnification.
Effect of VEGF-A and -B on CRC cell proliferation
To determine if VEGF-A or -B induced proliferation of CRC cells, HT-29 or SW480 cells were plated in 96-well plates at 1500 cells/well with 10% MEM-FBS, the medium was then changed to 5% MEM-FBS the next day and incubated overnight. Cells were then treated or not treated with VEGF-A (10 ng/ml) or VEGF-B (50 ng/ml) in 5% MEM-FBS, 1% MEM-FBS, or 0% MEM-FBS and incubated for 24, 48, 72, and 96 h. At the end of the incubation, 3-[4,5-dimethylthiazol-2-yl] 2,5 diphenyltetrazolium bromide (MTT; Sigma, St Louis, MO, USA) was added to a final concentration of 0.5 mg/ml, and cells were incubated for another 90 min. The medium and MTT were removed, dimethyl sulfoxide was added for 1 min, and absorption was read at 570 nm.
Statistical analyses
All statistical analyses were carried out with InStat Statistical Software (V2.03, GraphPad Software, San Diego, CA, USA), with P-values of less than 0.05 considered to be statistically significant.
